CELYAD ONCOLOGY (CYAD.BR) Stock Price, Quote, News and Overview
EBR:CYAD - Euronext Brussels - BE0974260896 - Common Stock - Currency: EUR
CYAD.BR Quote, Performance and Key Statistics
EBR:CYAD (3/21/2025, 7:00:00 PM)
0.57
+0.02 (+3.64%)
The current stock price of CYAD.BR is 0.57 EUR. In the past month the price decreased by -0.18%. In the past year, price increased by 60.56%.
CYAD.BR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1ABBV.MI | ABBVIE INC | 20.98 | 346.29B | ||
| 4AB.DE | ABBVIE INC | 20.77 | 342.83B | ||
| AMG.DE | AMGEN INC | 15.95 | 156.86B | ||
| GIS.DE | GILEAD SCIENCES INC | 23.07 | 122.41B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 1728.7 | 119.86B | ||
| ARGX.BR | ARGENX SE | 355.5 | 34.56B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.19B | ||
| IDP.DE | BIOGEN INC | 8.58 | 19.11B | ||
| 1MRNA.MI | MODERNA INC | N/A | 11.87B | ||
| 0QF.DE | MODERNA INC | N/A | 11.48B | ||
| BIO.DE | BIOTEST AG | 23.86 | 1.61B | ||
| GLPG.AS | GALAPAGOS NV | 21.54 | 1.59B |
Related stock screener links
About CYAD.BR
Company Profile
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 12 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
Company Info
CELYAD ONCOLOGY
Rue Andre Dumont 9
Mont-Saint-Guibert BRABANT-WALLON BE
Employees: 18
Company Website: https://www.celyad.com/
Investor Relations: http://www.celyad.com/investors.htm?lng=en
Phone: 3210394100
CELYAD ONCOLOGY / CYAD.BR FAQ
What is the stock price of CELYAD ONCOLOGY today?
The current stock price of CYAD.BR is 0.57 EUR. The price increased by 3.64% in the last trading session.
What is the ticker symbol for CELYAD ONCOLOGY stock?
The exchange symbol of CELYAD ONCOLOGY is CYAD and it is listed on the Euronext Brussels exchange.
On which exchange is CYAD.BR stock listed?
CYAD.BR stock is listed on the Euronext Brussels exchange.
What is CELYAD ONCOLOGY worth?
CELYAD ONCOLOGY (CYAD.BR) has a market capitalization of 12.88M EUR. This makes CYAD.BR a Nano Cap stock.
How many employees does CELYAD ONCOLOGY have?
CELYAD ONCOLOGY (CYAD.BR) currently has 18 employees.
What are the support and resistance levels for CELYAD ONCOLOGY (CYAD.BR) stock?
CELYAD ONCOLOGY (CYAD.BR) has a support level at 0.55 and a resistance level at 0.58. Check the full technical report for a detailed analysis of CYAD.BR support and resistance levels.
Should I buy CELYAD ONCOLOGY (CYAD.BR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CYAD.BR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CYAD.BR, evaluating the profitability, health, valuation and growth aspects
- CELYAD ONCOLOGY (CYAD.BR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CELYAD ONCOLOGY (CYAD.BR) Sales and EPS estimates to see what analysts future expectations are.
- CELYAD ONCOLOGY (CYAD.BR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CELYAD ONCOLOGY (CYAD.BR) Insider and Institutional Ownership to learn about the owners and their transactions.
- CELYAD ONCOLOGY (CYAD.BR) Stock Chart to make your own analysis
- CELYAD ONCOLOGY (CYAD.BR) Latest news and press-releases to stay up to date.
Does CELYAD ONCOLOGY (CYAD.BR) stock pay dividends?
CYAD.BR does not pay a dividend.
When does CELYAD ONCOLOGY (CYAD.BR) report earnings?
CELYAD ONCOLOGY (CYAD.BR) will report earnings on 2025-04-02, after the market close.
What is the Price/Earnings (PE) ratio of CELYAD ONCOLOGY (CYAD.BR)?
CELYAD ONCOLOGY (CYAD.BR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.24).
CYAD.BR Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CYAD.BR. When comparing the yearly performance of all stocks, CYAD.BR is one of the better performing stocks in the market, outperforming 89.18% of all stocks.
CYAD.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CYAD.BR. The financial health of CYAD.BR is average, but there are quite some concerns on its profitability.
CYAD.BR Financial Highlights
Over the last trailing twelve months CYAD.BR reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS increased by 82.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.89% | ||
| ROE | -134.01% | ||
| Debt/Equity | 0.14 |
CYAD.BR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 42% to CYAD.BR. The Buy consensus is the average rating of analysts ratings from 9 analysts.